ood morning, everyone. Damian Garde here, filling in for Ed Silverman on a day that marks the belated but not unwelcome return of warm weather here on Pharmalot’s satellite campus. Please find, as always, a few headlines from around the industry to get your day started. If you see something interesting out there, please do let us know. We’ll do the same.

There could be a nativist row brewing in the boardroom of Teva. According to Israeli news outlet Calcalist, the company’s CEO search committee has picked a foreigner as the leading candidate to replace departed chief Erez Vigodman. But some members of Teva’s board are demanding that an Israeli get the job, Calcalist says, which could set the stage for a fight in a boardroom once memorably described as “a nuthouse.”

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy